Skip to main content

BravoVax Co., Ltd.

BravoVax Co., Ltd. was founded in 2012. It is located at Building A9-2 (known as BravoVax Building), 858 Gaoxin Avenue, in the state-level biopharma development zone, Donghu hi-tech park of Wuhan, China. Relying on the experienced management team and international channels from Shanghai BravoBio Co., Ltd., and strong support from Humanwell Healthcare Group (one of the top 30 Chinese pharmaceutical companies and a listed group), BravoVax is developing rapidly. BravoVax is committed to the research and development of human vaccines and other biological products. The new pilot facility and R&D center are built at Wuhan biopharm industrial park. All colleagues of BravoVax hold a college and above degree, and more than 30% of them have master and above degrees as well as senior professional titles.

Based on strategic partnership with both domestic and international enterprises and institutions, BravoVax Co., Ltd. has signed agreements for technical development, technology transfer and cooperation projects. BravoVax’ pipeline covers viral, bacteria and recombinant vaccines, e.g. multivalent human rotavirus vaccine sublicensed from NIH/USA, anti-cavies recombinant vaccine with Academia Sinica, etc. BravoVax has all the required qualifications for technical import and export trade for biotechnology.

BravoVax regards human vaccine as its core business and promotes the development of the biopharmaceutical-related business targeting to be an environment-friendly and resource-friendly international enterprise. It will become a benchmark company in biopharm industry by supplying consumable vaccines with best quality to emerging market and undeveloped countries globally.